Home » Authors » Jennifer Boggs

Articles by Jennifer Boggs

Saving Cash, Refocusing, Isis Cuts Work Force By 40 Percent

Jan. 11, 2005

By Jennifer Boggs

Depomed Bringing In $22M For Trials, Marketing Of GR Products

Jan. 10, 2005

By Jennifer Boggs

Depomed Bringing In $22M For Trials, Marketing Of GR Products

Jan. 10, 2005

By Jennifer Boggs

Alexza Gets $52M In Private Round, Plans Clinical Trials

Jan. 7, 2005

By Jennifer Boggs

Alexza Molecular Delivery Corp. privately raised $52 million to thicken its clinical pipeline. (BioWorld Today)

Alexza Gets $52M In Private Round, Plans Clinical Trials

Jan. 7, 2005

By Jennifer Boggs

Alexza Molecular Delivery Corp. privately raised $52 million to thicken its clinical pipeline. (BioWorld Today)

Gathering Steam, Infinity Signs Deals With Novartis, J&J Unit

Jan. 6, 2005

By Jennifer Boggs

In rapid succession, Infinity Pharmaceuticals Inc. announced its second and third collaborations, forming with two pharmaceutical companies agreements that include equity investments. (BioWorld Today)

Gathering Steam, Infinity Signs Deals With Novartis, J&J Unit

Jan. 6, 2005

By Jennifer Boggs

In rapid succession, Infinity Pharmaceuticals Inc. announced its second and third collaborations, forming with two pharmaceutical companies agreements that include equity investments. (BioWorld Today)

Nereus, Vitae Raise Funds For Clinical Trials In 2005

Jan. 5, 2005

By Jennifer Boggs

Nereus, Vitae Raise Funds For Clinical Trials In 2005

Jan. 5, 2005

By Jennifer Boggs

OpGen's New CEO Focusing On Optical Mapping Platform Growth

Jan. 4, 2005

By Jennifer Boggs

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...